$SVRA
Savara Inc

2021 Q1 Form 10-K Financial Statement

#000156459021011919 Filed on March 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.780M $2.790M $3.300M
YoY Change -6.71% -15.45% 1.54%
% of Gross Profit
Research & Development $7.589M $10.16M $8.720M
YoY Change -42.51% 16.51% -11.56%
% of Gross Profit
Depreciation & Amortization $50.00K $70.00K $240.0K
YoY Change -79.34% -70.83% 71.43%
% of Gross Profit
Operating Expenses $10.41M $13.01M $12.08M
YoY Change -35.87% 7.7% -8.83%
Operating Profit -$10.41M -$31.51M
YoY Change 137.84%
Interest Expense -$593.0K -$730.0K -$290.0K
YoY Change 270.63% 151.72% -422.22%
% of Operating Profit
Other Income/Expense, Net $197.0K $0.00 $80.00K
YoY Change -75.98% -100.0% -42.86%
Pretax Income -$10.22M -$13.74M -$31.72M
YoY Change -33.73% -56.68% 143.63%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.22M -$13.74M -$31.72M
YoY Change -33.75% -56.68% 201.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$132.7K -$226.3K -$723.2K
COMMON SHARES
Basic Shares Outstanding 54.24M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $192.7M $82.20M $121.8M
YoY Change 83.52% -32.51% 9.93%
Cash & Equivalents $55.98M $22.88M $49.80M
Short-Term Investments $136.7M $59.30M $72.00M
Other Short-Term Assets $600.0K $1.200M $700.0K
YoY Change -33.33% 71.43% -12.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $194.8M $85.12M $124.1M
YoY Change 81.3% -31.39% 9.46%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $156.0K $352.0K
YoY Change -65.99% -55.68% -32.57%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000M $250.0K $673.0K
YoY Change -23.43% -62.85% 413.74%
Total Long-Term Assets $12.80M $12.62M $12.14M
YoY Change 2.15% 4.02% -68.84%
TOTAL ASSETS
Total Short-Term Assets $194.8M $85.12M $124.1M
Total Long-Term Assets $12.80M $12.62M $12.14M
Total Assets $207.6M $97.75M $136.2M
YoY Change 73.04% -28.24% -10.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $2.595M $3.409M
YoY Change 120.05% -23.88% -12.12%
Accrued Expenses $4.484M $5.579M $5.471M
YoY Change -31.04% 1.97% 62.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M
YoY Change
Total Short-Term Liabilities $7.207M $8.174M $10.88M
YoY Change -6.75% -24.87% 49.99%
LONG-TERM LIABILITIES
Long-Term Debt $25.24M $25.10M $23.10M
YoY Change 2.2% 8.68% -5.71%
Other Long-Term Liabilities $58.00K $84.00K $513.0K
YoY Change -70.85% -83.63% 632.86%
Total Long-Term Liabilities $25.30M $25.19M $513.0K
YoY Change 12614.57% 4809.94% 632.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.207M $8.174M $10.88M
Total Long-Term Liabilities $25.30M $25.19M $513.0K
Total Liabilities $32.51M $33.36M $34.51M
YoY Change -0.46% -3.31% -21.7%
SHAREHOLDERS EQUITY
Retained Earnings -$267.7M -$257.5M -$207.9M
YoY Change 23.87% 60.26%
Common Stock $320.9M $309.6M
YoY Change 3.66% 30.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $175.1M $64.38M $101.7M
YoY Change
Total Liabilities & Shareholders Equity $207.6M $97.75M $136.2M
YoY Change 73.0% -28.24% -10.56%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2019 Q4
OPERATING ACTIVITIES
Net Income -$10.22M -$13.74M -$31.72M
YoY Change -33.75% -56.68% 201.68%
Depreciation, Depletion And Amortization $50.00K $70.00K $240.0K
YoY Change -79.34% -70.83% 71.43%
Cash From Operating Activities -$9.597M -$12.30M -$9.940M
YoY Change -26.62% 23.74% -5.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0% -83.33%
Acquisitions
YoY Change
Other Investing Activities -$77.74M -$370.0K $16.76M
YoY Change -5388.44% -102.21% 1702.15%
Cash From Investing Activities -$77.74M -$380.0K $16.75M
YoY Change 4255.13% -102.27% 1825.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.5M 0.000 25.25M
YoY Change -25951.07% -100.0% 177.78%
NET CHANGE
Cash From Operating Activities -9.597M -12.30M -9.940M
Cash From Investing Activities -77.74M -380.0K 16.75M
Cash From Financing Activities 120.5M 0.000 25.25M
Net Change In Cash 33.10M -12.68M 32.06M
YoY Change -316.51% -139.55% -6037.04%
FREE CASH FLOW
Cash From Operating Activities -$9.597M -$12.30M -$9.940M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$9.597M -$12.30M -$9.930M
YoY Change -26.65% 23.87% -4.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14264000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
26852000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
255000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49804000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
71957000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2306000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
124067000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
352000
CY2019Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11111000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2020Q4 us-gaap Liabilities
Liabilities
33362000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35038000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13081000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020 svra Change In Ownership Interest Period
ChangeInOwnershipInterestPeriod
P3Y
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P15Y6M
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38781000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
101698000
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
SVRA
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
116495337
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54235926
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54152955
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
311000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54152955
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-78173000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1006000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-296000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320893000
CY2019 svra Tax Credit Income
TaxCreditIncome
1213000
CY2019 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-213000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257507000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97745000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
257000
CY2019 us-gaap Operating Expenses
OperatingExpenses
79025000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-78000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
108219000
CY2019 svra Issuance Of Securities In Private Placement Net Closing Costs
IssuanceOfSecuritiesInPrivatePlacementNetClosingCosts
25247000
CY2019 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
29592000
CY2019 svra Issuance Of Common Stock Upon Settlement Of Contingent Liability
IssuanceOfCommonStockUponSettlementOfContingentLiability
12478000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
111000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4441000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-296000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-78173000
CY2020 svra Stock Issued During Period Value Licensing Of Assets
StockIssuedDuringPeriodValueLicensingOfAssets
2120000
CY2020 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
2290000
CY2020 svra Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Milestone Warrants Net
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet
1827000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2020 svra Adjustments To Additional Paid In Capital Closing Costs For Previous Issuance Of Securities In Private Placement
AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement
120000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
29000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5107000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1006000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2020 us-gaap Profit Loss
ProfitLoss
-49615000
CY2019 us-gaap Profit Loss
ProfitLoss
-78173000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
255000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
311000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
438000
CY2019 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-213000
CY2019 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
264000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
699000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
26852000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5367000
CY2020 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
116000
CY2020 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
29000
CY2019 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
-72000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
158000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-78000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
507000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
582000
CY2020 svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
-55000
CY2019 svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
1161000
CY2019 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
4000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5107000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4441000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-148000
CY2019 svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
-131000
CY2020 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-1140000
CY2019 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
568000
CY2020 svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-431000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39836000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45123000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
148000
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3247000
CY2020 svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
86083000
CY2019 svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
122945000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
89650000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
124700000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8780000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
14133000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9053000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15740000
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
514000
CY2020 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
1827000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25247000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29592000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
110000
CY2019 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
41000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3689000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54908000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
170000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-22000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26924000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25503000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24301000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22880000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2020 svra Common Stock Issued For Acquired In Process Research And Development Net
CommonStockIssuedForAcquiredInProcessResearchAndDevelopmentNet
2120000
CY2019 svra Non Cash Settlement Of Contingent Consideration
NonCashSettlementOfContingentConsideration
12478000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2470000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2099000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257500000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39800000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22900000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
59300000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Use of Estimates </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management’s estimates include those related to the accrual of research and development and general and administrative costs, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.</span></p>
CY2020Q4 us-gaap Goodwill
Goodwill
0
CY2019 svra In Process Research And Development Decrease
InProcessResearchAndDevelopmentDecrease
300000
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7400000
CY2019Q4 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
19400000
CY2019Q4 us-gaap Goodwill Fair Value Disclosure
GoodwillFairValueDisclosure
0
CY2020 svra In Process Research And Development Increase
InProcessResearchAndDevelopmentIncrease
1100000
CY2020 svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Concentration of Credit Risk </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and short-term investments held in money market accounts. The Company places its cash and cash equivalents and money market accounts with a limited number of financial institutions and at times may exceed the amount of insurance provided on such deposits. </span></p>
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
653000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
364000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
453000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
247000
CY2019Q4 svra Foreign Currency Exchange Derivative Current
ForeignCurrencyExchangeDerivativeCurrent
7000
CY2020Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
194000
CY2019Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
251000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2933000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2306000
CY2020 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
8432000
CY2020Q4 svra Contingent Milestones Commitments Incurred
ContingentMilestonesCommitmentsIncurred
0
CY2020Q4 svra Contingent Milestones Commitments Remunerated
ContingentMilestonesCommitmentsRemunerated
0
CY2020Q4 svra Contingent Milestones Commitments Accrued
ContingentMilestonesCommitmentsAccrued
0
CY2020Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1042000
CY2019Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1253000
CY2020Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
591000
CY2019Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
184000
CY2020Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2627000
CY2019Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2018000
CY2020Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
853000
CY2019Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
1710000
CY2020Q4 svra Accrued Compensation
AccruedCompensation
1920000
CY2019Q4 svra Accrued Compensation
AccruedCompensation
1303000
CY2020Q4 svra Accrued Lease Liability
AccruedLeaseLiability
179000
CY2019Q4 svra Accrued Lease Liability
AccruedLeaseLiability
440000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5471000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59307000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59308000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71909000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71957000
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2129000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2026000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1973000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1674000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
352000
CY2020 us-gaap Depreciation
Depreciation
300000
CY2019 us-gaap Depreciation
Depreciation
300000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8333000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18167000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2020Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
1134000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
149000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
113000
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
25104000
CY2020Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
25104000
CY2020Q4 svra Upfront Cash Payment Payable
UpfrontCashPaymentPayable
3200000
CY2020 svra Upfront Payment Common Stock Shares Issued
UpfrontPaymentCommonStockSharesIssued
1000000
CY2020 svra Upfront Payment Common Stock Issued Value
UpfrontPaymentCommonStockIssuedValue
2100000
CY2020 svra Upfront Payment Research And Development Expense
UpfrontPaymentResearchAndDevelopmentExpense
5400000
CY2020Q4 svra License Agreement Contingent Consideration Liability
LicenseAgreementContingentConsiderationLiability
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
CY2019Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25247000
CY2020Q4 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
201000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54152955
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50790441
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
45133986
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44544392
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
38384247
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
200000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-217000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
959000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942000
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2017Q4 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
CY2020 svra Lease Commencement Date
LeaseCommencementDate
2018-11-01
CY2020 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2020Q4 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
194000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
67000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
261000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
253000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
476000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
300000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
200000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5107000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4441000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30396000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-52440000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19219000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-25733000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49615000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-78173000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10419000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16416000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14311000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12780000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1904000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2855000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
68000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
278000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-847000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-312000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
5671000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1209000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
854000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14300000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12800000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-78173000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49615000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78173000
CY2020 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-49615000
CY2019 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-78173000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59309090
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40027758
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2143000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
524000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
516000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
524000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2659000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38256000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30953000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
230000
CY2020Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1332000
CY2019Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
97000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
17620000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15654000
CY2020Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
1806000
CY2019Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
365000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59244000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47069000
CY2020Q4 svra Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
58720000
CY2019Q4 svra Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
44410000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58720000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44410000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
54800000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
40300000
CY2020Q4 svra Percentage Increase In Shareholders Ownership Interest
PercentageIncreaseInShareholdersOwnershipInterest
0.05
CY2020Q4 svra Minimum Percentage Points Change In Ownership Interest
MinimumPercentagePointsChangeInOwnershipInterest
0.0050
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38578449
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37988855
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000

Files In Submission

Name View Source Status
0001564590-21-011919-index-headers.html Edgar Link pending
0001564590-21-011919-index.html Edgar Link pending
0001564590-21-011919.txt Edgar Link pending
0001564590-21-011919-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcmmchdwaq2a000001.jpg Edgar Link pending
gcmmchdwaq2a000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10k_20201231.htm Edgar Link pending
svra-10k_20201231_htm.xml Edgar Link completed
svra-20201231.xsd Edgar Link pending
svra-20201231_cal.xml Edgar Link unprocessable
svra-20201231_def.xml Edgar Link unprocessable
svra-20201231_lab.xml Edgar Link unprocessable
svra-20201231_pre.xml Edgar Link unprocessable
svra-ex109_66.htm Edgar Link pending
svra-ex231_8.htm Edgar Link pending
svra-ex311_14.htm Edgar Link pending
svra-ex312_9.htm Edgar Link pending
svra-ex321_10.htm Edgar Link pending